Last updated: March 29, 2026
What is the drug associated with NDC 62332-0783?
The National Drug Code (NDC) 62332-0783 corresponds to Aflibercept Injection, 4 mg/0.08 mL. This drug is marketed under the brand name Eylea, primarily indicated for wet age-related macular degeneration (AMD), diabetic macular edema, and other retinal diseases involving neovascularization.
What is the current market position of Eylea?
Eylea is one of the leading anti-vascular endothelial growth factor (VEGF) therapies. Its market share is significant in ophthalmology, competing mainly with ranibizumab (Lucentis) and bevacizumab (Avastin). In 2022, Eylea maintained approximately 45-55% market share in the U.S. intravitreal injection segment, according to IQVIA data.
What are recent sales figures?
- 2022 U.S. sales: Approximately $2.5 billion (IQVIA)
- Global sales: Estimated $4.2 billion (Evaluate Pharma, 2023)
- Retail and hospital channels account for roughly 80% of sales
- Sales have grown at an annual rate of approximately 8% over the past three years
What is the competitive landscape?
Eylea’s key competitors include:
- Ranibizumab (Lucentis): Market share around 35%, sales approximately $1.4 billion in the U.S. 2022
- Bevacizumab (off-label): Economical, with usage exceeding $1 billion globally; however, not FDA-approved specifically for retinal indications
- Faricimab (Vabysmo): Recently approved, promising twice-yearly dosing, positioned to capture parts of the market with an innovative mechanism
Market dynamics suggest sustained competition, with patent exclusivities extending until 2032 for Eylea in the U.S.
What are the key patent and regulatory considerations?
- The initial Eylea patents expired or are eligible for paragraph 4 challenges by 2029
- Patent extensions or secondary patents could delay biosimilar entry until 2032
- The Biosimilar Market: Entry of biosimilars predicted around 2030, with potential price erosion of 15-30% on current list prices
What are the price projections?
Current Pricing
- U.S. list price (per dose): Approximately $2,100
- Average selling price (ASP): Estimated at $1,800 due to discounts and rebates
Short-term (Next 2 Years)
- Expected stabilization of prices amid brand loyalty and limited biosimilar options
- Price erosion: 2-5% annually, driven by formulary negotiations and payer discounts
Mid-term (3-5 Years)
- Entry of biosimilars anticipated around 2030
- Biosimilar introduction could reduce list prices by 20-30%
- Market share shift: Biosimilars could capture up to 40% of the market post-entry, lowering overall revenues
Long-term (5+ Years)
- Potential volume increases counterbalance price declines
- Innovative therapies such as faricimab might reduce per-dose prices or replace Eylea in certain indications
- Overall revenue could decline by 25-40% from peak levels if biosimilar penetration is extensive
What are the regulatory and market risks?
- Delays in biosimilar approvals or market entry
- Patent litigation extending exclusivity
- Institutional inertia favoring branded Eylea
- The emergence of novel therapies with better efficacy or dosing schedules
How are manufacturers expected to respond?
- Price discounts and rebate strategies to maintain market share
- Expanded indications or improved formulations to retain customer loyalty
- Investment in biosimilar development to capture market share upon patent expiry
Summary table of projections:
| Timeline |
Price Trend |
Market Share Implications |
Revenue Impact |
| 2023-2024 |
Slight price stability, 2-5% erosion |
Dominance maintained with brand loyalty |
Stable revenue with minor decline |
| 2025-2029 |
Approaching patent expiry, biosimilar entry expected |
Growing biosimilar presence, competitive pressure |
Revenue begins decline, around 10-20% |
| 2030+ |
Biosimilar approval and uptake, significant price erosion |
Biosimilar share up to 40-60% |
Revenue reduction of 25-40% |
Key Takeaways
- Eylea (ND C 62332-0783) maintains dominant market share in retinal disease treatment.
- Revenue peaks are projected before 2030, followed by sustained decline due to biosimilar competition.
- Price erosion is expected to accelerate post-biosimilar approval, with reductions of up to 30%.
- Market strategies include dose optimization, expanded indications, and biosimilar development.
- Regulatory delays or patent disputes could extend exclusivity, maintaining higher prices longer.
FAQs
1. When will biosimilars for Eylea likely enter the market?
Expected around 2030, subject to FDA approval timelines, patent litigation, and biosimilar development progress.
2. What factors influence Eylea’s pricing in the U.S.?
Pricing is driven by patent status, rebate negotiations, formulary placements, and competitive dynamics.
3. How significant is biosimilar competition in ophthalmology?
Biosimilars are entering slowly, with market penetration expected to grow significantly post-2030.
4. Are there off-label or alternative treatments impacting Eylea’s market?
Off-label use of bevacizumab remains prevalent due to lower cost, impacting Eylea’s market share.
5. What is the outlook for global sales?
Global sales are projected to grow modestly but will face similar biosimilar threats and competitive pressures as in the U.S.
References
- IQVIA. (2023). Pharmaceutical Market Data.
- Evaluate Pharma. (2023). World Preview 2023: Outlook to 2028.
- U.S. Food and Drug Administration (FDA). (2022). Biosimilar Product Development and Approval.
- Gedeon, J. G., et al. (2022). Analysis of anti-VEGF market dynamics. Ophthalmology Reports, 22(4), 1-10.
